This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (108)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Pathology & Laboratory Medicine  • Substance Abuse/ Alcoholism  • Immunology  • Immunologic Disorders  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Plasma Viral Load and CD4⁺ Cell Count

David Vlahov, PhD; Neil Graham, MD; Donald Hoover, PhD; Colin Flynn, ScM; John G. Bartlett, MD; Joseph B. Margolick, MD, PhD; Cynthia M. Lyles, PhD; Kenrad E. Nelson, MD; Dawn Smith, MD; Scott Holmberg, MD; Homayoon Farzadegan, PhD

JAMA. 1998;279:35-40.

Context.— Plasma human immunodeficiency virus type 1 (HIV-1) viral load and CD4⁺ cell count are used to predict prognosis of persons infected with HIV. However, whether combining these markers improves prognostic accuracy and whether they predict prognosis for injection drug users (IDUs) and nonwhite persons infected with HIV has not been extensively investigated.

Objective.— To evaluate plasma viral load and CD4⁺ cell count as prognostic indicators for the acquired immunodeficiency syndrome (AIDS) and infectious disease deaths.

Design.— Cohort study initiated in 1988 and 1989 with follow-up for up to 7.9 years.

Participants.— Injection drug users infected with HIV recruited from the community in Baltimore, Md.

Main Outcome Measures.— Plasma HIV-1 RNA and CD4⁺ cell count measured at baseline compared with time to first clinical AIDS diagnosis and death due to an infectious disease.

Results.— Of 522 subjects, 96% were African American, 80% were male, 96% injected drugs within the past 6 months, and the median age was 33 years. A total of 146 cases of AIDS and 119 infectious disease deaths were seen during a median follow-up period of 6.4 years. Time-fixed baseline levels of viral load and CD4⁺ cell count were independent predictors of progression to AIDS and infectious disease deaths, but in proportional hazards models, viral load had better predictive value than CD4⁺ cell count. Kaplan-Meier analysis of time to AIDS and to infectious disease deaths by viral load (<500, 500-9999, 10000-29999, 30000 copies/mL) at 3 levels of CD4⁺ cell count (<0.20, 0.20-0.49, and 0.50x10⁹/L [<200, 200-499, and 500/µL]) was reduced to a 5-stage classification scheme using a backward stepwise regression procedure. The 5-year cumulative probabilities for AIDS and infectious disease deaths ranged from 0% and 0%, respectively, for group I (viral load, <500 copies/mL; CD4⁺ cell count, 0.50x10⁹/L) to 81.2% and 76.1% respectively, for group V (viral load, 10000 copies/mL; CD4⁺ cell count, 0.20x10⁹/L).

Conclusions.— In this study, plasma HIV-1 viral load independently and in combination with CD4⁺ cell count measurements provided powerful prognostic information for progression to AIDS and death caused by infectious disease in a population of predominantly African American IDUs. Combining categories of both markers provided a simple method for prognostically staging HIV disease.

From the Departments of Epidemiology (Drs Vlahov, Graham, Hoover, Lyles, Nelson, and Farzadegan and Mr Flynn) and Molecular Microbiology and Immunology (Dr Margolick), The Johns Hopkins School of Hygiene and Public Health, Baltimore, Md; the Department of Medicine (Dr Bartlett), The Johns Hopkins School of Medicine, Baltimore, Md; and the Division of HIV/AIDS (Drs Smith and Holmberg), the Centers for Disease Control and Prevention, Atlanta, Ga.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cofactors for Low Serum Albumin Levels Among HIV-Infected Individuals in Southern India
Sundaram et al.
J Int Assoc Physicians AIDS Care (Chic Ill) 2009;8:161-164.
ABSTRACT  

Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age
Sanders et al.
ANN INTERN MED 2008;148:889-903.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy
Sanders et al.
NEJM 2005;352:570-585.
ABSTRACT | FULL TEXT  

APOBEC3G Genetic Variants and Their Influence on the Progression to AIDS
An et al.
J. Virol. 2004;78:11070-11076.
ABSTRACT | FULL TEXT  

Can patient self-management help explain the SES health gradient?
Goldman and Smith
Proc. Natl. Acad. Sci. USA 2002;99:10929-10934.
ABSTRACT | FULL TEXT  

Risk Factors for Cognitive Impairment in HIV-1-Infected Persons With Different Risk Behaviors
De Ronchi et al.
Arch Neurol 2002;59:812-818.
ABSTRACT | FULL TEXT  

Identifying Undiagnosed Human Immunodeficiency Virus: The Yield of Routine, Voluntary Inpatient Testing
Walensky et al.
Arch Intern Med 2002;162:887-892.
ABSTRACT | FULL TEXT  

Health and Federal Budgetary Effects of Increasing Access to Antiretroviral Medications for HIV by Expanding Medicaid
Kahn et al.
Am. J. Public Health 2001;91:1464-1473.
ABSTRACT | FULL TEXT  

Selection by Indication of Potent Antiretroviral Therapy Use in a Large Cohort of Women Infected with Human Immunodeficiency Virus
Ahdieh et al.
Am J Epidemiol 2000;152:923-933.
ABSTRACT | FULL TEXT  

The Natural History of Hepatitis C Virus Infection: Host, Viral, and Environmental Factors
Thomas et al.
JAMA 2000;284:450-456.
ABSTRACT | FULL TEXT  

Plasma HIV Viral Load in Patients with Hemophilia and Late-Stage HIV Disease: A Measure of Current Immune Suppression
Engels et al.
ANN INTERN MED 1999;131:256-264.
ABSTRACT | FULL TEXT  

Comparison of Two Measures of Human Immunodeficiency Virus (HIV) Type 1 Load in HIV Risk Groups
Lyles et al.
J. Clin. Microbiol. 1998;36:3647-3652.
ABSTRACT | FULL TEXT  

Prognostic Indicators for Disease in HIV-Infected Drug Users
JWatch Infect. Diseases 1998;1998:19-19.
FULL TEXT